Glutamine supplementation for critically ill adults
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Glutamine is a non-essential amino acid which is abundant in the healthy human body. There are studies reporting that plasma glutamine levels are reduced in patients with critical illness or following major surgery, suggesting that glutamine may be a conditionally essential amino acid in situations of extreme stress. In the past decade, several clinical trials examining the effects of glutamine supplementation in patients with critical illness or receiving surgery have been done, and the systematic review of this clinical evidence has suggested that glutamine supplementation may reduce infection and mortality rates in patients with critical illness. However, two recent large-scale randomized clinical trials did not find any beneficial effects of glutamine supplementation in patients with critical illness. OBJECTIVES: The objective of this review was to:1. assess the effects of glutamine supplementation in critically ill adults and in adults after major surgery on infection rate, mortality and other clinically relevant outcomes;2. investigate potential heterogeneity across different patient groups and different routes for providing nutrition. SEARCH METHODS: We searched the Cochrane Anaesthesia Review Group (CARG) Specialized Register; Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library (2013, Issue 5); MEDLINE (1950 to May 2013); EMBASE (1980 to May 2013) and Web of Science (1945 to May 2013). SELECTION CRITERIA: We included controlled clinical trials with random or quasi-random allocation that examined glutamine supplementation versus no supplementation or placebo in adults with a critical illness or undergoing elective major surgery. We excluded cross-over trials. DATA COLLECTION AND ANALYSIS: Two authors independently extracted the relevant information from each included study using a standardized data extraction form. For infectious complications and mortality and morbidity outcomes we used risk ratio (RR) as the summary measure with the 95% confidence interval (CI). We calculated, where appropriate, the number needed to treat to benefit (NNTB) and the number needed to treat to harm (NNTH). We presented continuous data as the difference between means (MD) with the 95% CI. MAIN RESULTS: Our search identified 1999 titles, of which 53 trials (57 articles) fulfilled our inclusion criteria. The 53 included studies enrolled a total of 4671 participants with critical illness or undergoing elective major surgery. We analysed seven domains of potential risk of bias. In 10 studies the risk of bias was evaluated as low in all of the domains. Thirty-three trials (2303 patients) provided data on nosocomial infectious complications; pooling of these data suggested that glutamine supplementation reduced the infectious complications rate in adults with critical illness or undergoing elective major surgery (RR 0.79, 95% CI 0.71 to 0.87, P < 0.00001, I² = 8%, moderate quality evidence). Thirty-six studies reported short-term (hospital or less than one month) mortality. The combined rate of mortality from these studies was not statistically different between the groups receiving glutamine supplement and those receiving no supplement (RR 0.89, 95% CI 0.78 to 1.02, P = 0.10, I² = 22%, low quality evidence). Eleven studies reported long-term (more than six months) mortality; meta-analysis of these studies (2277 participants) yielded a RR of 1.00 (95% CI 0.89 to 1.12, P = 0.94, I² = 30%, moderate quality evidence). Subgroup analysis of infectious complications and mortality outcomes did not find any statistically significant differences between the predefined groups. Hospital length of stay was reported in 36 studies. We found that the length of hospital stay was shorter in the intervention group than in the control group (MD -3.46 days, 95% CI -4.61 to -2.32, P < 0.0001, I² = 63%, low quality evidence). Slightly prolonged intensive care unit (ICU) stay was found in the glutamine supplemented group from 22 studies (2285 participants) (MD 0.18 days, 95% CI 0.07 to 0.29, P = 0.002, I² = 11%, moderate quality evidence). Days on mechanical ventilation (14 studies, 1297 participants) was found to be slightly shorter in the intervention group than in the control group (MD - 0.69 days, 95% CI -1.37 to -0.02, P = 0.04, I² = 18%, moderate quality evidence). There was no clear evidence of a difference between the groups for side effects and quality of life, however results were imprecise for serious adverse events and few studies reported on quality of life. Sensitivity analysis including only low risk of bias studies found that glutamine supplementation had beneficial effects in reducing the length of hospital stay (MD -2.9 days, 95% CI -5.3 to -0.5, P = 0.02, I² = 58%, eight studies) while there was no statistically significant difference between the groups for all of the other outcomes. AUTHORS' CONCLUSIONS: This review found moderate evidence that glutamine supplementation reduced the infect
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estimating the mean and variance from the median, range, and the size of a sample
Hozo, S. P., Djulbegovic, B., & Hozo, I. (2005) · BMC Medical Research Methodology · doi:10.1186/1471-2288-5-13 · Cited by 9,062
What is ‘quality of evidence’ and why is it important to clinicians?
Guyatt, G. H., Oxman, A. D., Kunz, R., Vist, G. E., Falck-Ytter, Y., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39490.551019.be · Cited by 3,250
ESPEN guidelines on parenteral nutrition: intensive care
Singer, P., Berger, M. M., Van den Berghe, G., Biolo, G., Calder, P., Forbes, A., Griffiths, R., Kreyman, G., Leverve, X., & Pichard, C. (2009) · Clinical Nutrition · doi:10.1016/j.clnu.2009.04.024 · Cited by 1,907
ESPEN guidelines on enteral nutrition: intensive care
Kreymann, K. G., Berger, M. M., Deutz, N. E. P., Hiesmayr, M., Jolliet, P., Kazandjiev, G., Nitenberg, G., van den Berghe, G., Wernerman, J., Ebner, C., et al. (2006) · Clinical Nutrition · doi:10.1016/j.clnu.2006.01.021 · Cited by 1,366
A Randomized Trial of Glutamine and Antioxidants in Critically Ill Patients
Heyland, D., Muscedere, J., Wischmeyer, P. E., Cook, D., Jones, G., Albert, M., Elke, G., Berger, M. M., & Day, A. G. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212722 · Cited by 904
Houdijk, A. P., Rijnsburger, E. R., Jansen, J., Wesdorp, R. I., Weiss, J. K., McCamish, M. A., Teerlink, T., Meuwissen, S. G., Haarman, H. J. T. M., Thijs, L. G., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02007-8 · Cited by 620
Andrews, P. J. D., Avenell, A., Noble, D. W., Campbell, M. K., Croal, B. L., Simpson, W. G., Vale, L. D., Battison, C. G., Jenkinson, D. J., Cook, J. A., et al. (2011) · BMJ · doi:10.1136/bmj.d1542 · Cited by 379
Grau, T., Bonet, A., Miñambres, E., Piñeiro, L., Irles, J. A., Robles, A., Acosta, J., Herrero, I., Palacios, V., Lopez, J., et al. (2011) · Critical Care Medicine · doi:10.1097/ccm.0b013e31820eb774 · Cited by 149
Bakalar, B., Duska, F., Pachl, J., Fric, M., Otahal, M., Pazout, J., & Andel, M. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000196829.30741.d4 · Cited by 136
WERNERMAN, J., KIRKETEIG, T., ANDERSSON, B., BERTHELSON, H., ERSSON, A., FRIBERG, H., GUTTORMSEN, A. B., HENDRIKX, S., PETTILÄ, V., ROSSI, P., et al. (2011) · Acta Anaesthesiologica Scandinavica · doi:10.1111/j.1399-6576.2011.02453.x · Cited by 132
Cited by
Weiss, S. L., Peters, M. J., Alhazzani, W., Agus, M. S. D., Flori, H. R., Inwald, D. P., Nadel, S., Schlapbach, L. J., Tasker, R. C., Argent, A. C., et al. (2020) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0000000000002198 · Cited by 1,228
Weiss, S. L., Peters, M. J., Alhazzani, W., Agus, M. S. D., Flori, H. R., Inwald, D. P., Nadel, S., Schlapbach, L. J., Tasker, R. C., Argent, A. C., et al. (2020) · Intensive Care Medicine · doi:10.1007/s00134-019-05878-6 · Cited by 606
Acquired Amino Acid Deficiencies: A Focus on Arginine and Glutamine
Morris, C. R., Hamilton‐Reeves, J., Martindale, R. G., Sarav, M., & Ochoa Gautier, J. B. (2017) · Nutrition in Clinical Practice · doi:10.1177/0884533617691250 · Cited by 160
Enteral glutamine supplementation in critically ill patients: a systematic review and meta-analysis
van Zanten, A. R. H., Dhaliwal, R., Garrel, D., & Heyland, D. K. (2015) · Critical Care · doi:10.1186/s13054-015-1002-x · Cited by 130
“However, in the latest meta-analysis published by the Cochrane Database of Systematic Reviews, signals for mortality reduction were lost and only moderate- and low-level evidence on reduction of morbidity was found, with high risk of overall bias, suspected publication bias and moderate to substantial heterogeneity wi…”
BackgroundLewis, S. R., Schofield-Robinson, O. J., Alderson, P., & Smith, A. F. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012276.pub2 · Cited by 118
Stehle, P., Ellger, B., Kojic, D., Feuersenger, A., Schneid, C., Stover, J., Scheiner, D., & Westphal, M. (2017) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2016.09.007 · Cited by 98
Immunonutrition in Critical Illness: What Is the Role?
McCarthy, M. S., & Martindale, R. G. (2018) · Nutrition in Clinical Practice · doi:10.1002/ncp.10102 · Cited by 58
Soeters, P., Bozzetti, F., Cynober, L., Elia, M., Shenkin, A., & Sobotka, L. (2016) · Clinical Nutrition · doi:10.1016/j.clnu.2015.08.008 · Cited by 40
“This treatment has been proven to be safe and efficient on the basis of relevant clinical end points in small trials in homogeneous patient groups [22].”
BackgroundTherapeutic benefits of glutamine: An umbrella review of meta-analyses
McRae, M. P. (2017) · Biomedical Reports · doi:10.3892/br.2017.885 · Cited by 39
(2016) · PubMed · doi:10.6133/apjcn.092015.24 · Cited by 14
Metadata
- Authors
- Tao, K.-M., Li, X.-Q., Yang, L.-Q., Yu, W.-F., Lu, Z.-J., Sun, Y.-M., & Wu, F.-X.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2014-09-09
- Volume
- 2018
- Issue
- 12
- Pages
- CD010050-CD010050
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1796863844
- Cited by
- 90
- References
- 10
- FWCI
- 9.18
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.